We are live on ! Find out more
DMKJ

David M. Knott Jr Portfolio holdings

AUM $189M Turnover 22.11%
1-Year Est. Return 67.72%
This Fund
S&P 500
This Quarter Est. Return
+1.58%
1 Year Est. Return
+67.72%
3 Year Est. Return
+169.37%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$251M
AUM Growth
-$32.1M
Cap. Flow
-$32.3M
Cap. Flow %
-12.88%
Top 10 Hldgs %
68.46%
Holding
112
New
6
Increased
15
Reduced
10
Closed
13
Avg Time Held
1.6 years
Top 10 Avg Time Held
1.4 years
Top 20 Avg Time Held
1.2 years

Top Buys

Rank Stock Value
1
DCGO icon
DocGo
DCGO
+$3.77M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$1.73M
3
VRNA
Verona Pharma
VRNA
+$1.28M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$803K
5
MREO icon
Mereo BioPharma
MREO
+$667K

Top Sells

Rank Stock Value
1
FTAI icon
FTAI Aviation
FTAI
+$16.8M
2
WEST icon
Westrock Coffee
WEST
+$4.89M
3
CLOZ icon
Panagram BBB-B CLO ETF
CLOZ
+$4.73M
4
JAAA icon
Janus Henderson AAA CLO ETF
JAAA
+$3.64M
5
LGND icon
Ligand Pharmaceuticals
LGND
+$2.39M

Sector Composition

Rank Sector Weight
1 Healthcare 30.74%
2 Materials 28.51%
3 Financials 14.16%
4 Miscellaneous 12.73%
5 Communication Services 8.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CLMT icon
1
Calumet Specialty Products
CLMT
$5.16B
$69.4M 27.7%
4,325,000
– –
2021 Q4
10 quarters
APO icon
2
Apollo Global Management
APO
$66.1B
$26.6M 10.6%
225,000
– –
2021 Q4
10 quarters
GOOG icon
3
Alphabet (Google) Class C
GOOG
$4.22T
$20.6M 8.21%
112,220
– –
2021 Q4
10 quarters
CLOZ icon
4
Panagram BBB-B CLO ETF
CLOZ
$783M
$14.6M 5.84%
542,868
-176,500
-25% -$4.73M
2023 Q3
3 quarters
DCGO icon
5
DocGo
DCGO
$26.2M
$9.49M 3.79%
3,070,850
+1,145,850
+60% +$3.77M
2021 Q4
10 quarters
LGND icon
6
Ligand Pharmaceuticals
LGND
$6.02B
$7.16M 2.86%
85,000
-30,000
-26% -$2.39M
2021 Q4
10 quarters
PFE icon
7
Pfizer
PFE
$169B
$6.96M 2.78%
248,737
+1,200
+0.5% +$33K
2021 Q4
10 quarters
ICLO icon
8
Invesco AAA CLO Floating Rate Note ETF
ICLO
$603M
$6.11M 2.44%
237,753
-69,266
-23% -$1.78M
2023 Q3
3 quarters
ARDX icon
9
Ardelyx
ARDX
$849M
$5.73M 2.29%
772,867
-52,133
-6% -$367K
2022 Q3
7 quarters
AVDL
10
DELISTED
Avadel Pharmaceuticals
AVDL
$4.68M 1.87%
333,000
– –
2021 Q4
10 quarters
JPM icon
11
JPMorgan Chase
JPM
$890B
$4.24M 1.69%
20,985
– –
2021 Q4
10 quarters
OABI icon
12
OmniAb
OABI
$672M
$4.19M 1.67%
1,118,505
+15,000
+1% +$68.4K
2022 Q4
6 quarters
VKTX icon
13
Viking Therapeutics
VKTX
$3.41B
$4.03M 1.61%
76,036
-25,400
-25% -$1.66M
2021 Q4
10 quarters
CPRX icon
14
DELISTED
Catalyst Pharmaceutical
CPRX
$3.28M 1.31%
212,000
+24,148
+13% +$376K
2023 Q4
2 quarters
VRNA
15
DELISTED
Verona Pharma
VRNA
$2.94M 1.17%
203,000
+88,000
+77% +$1.28M
2023 Q4
2 quarters
JAAA icon
16
Janus Henderson AAA CLO ETF
JAAA
$32.1B
$2.72M 1.08%
53,397
-71,682
-57% -$3.64M
2023 Q3
3 quarters
DMRC icon
17
Digimarc Corp
DMRC
$145M
$2.59M 1.03%
83,557
– –
2024 Q1
1 quarter
INZY icon
18
DELISTED
Inozyme Pharma
INZY
$2.52M 1%
564,549
– –
2023 Q1
5 quarters
GSK icon
19
GSK
GSK
$99.1B
$2.5M 1%
65,000
– –
2022 Q3
7 quarters
IMVT icon
20
Immunovant
IMVT
$5.81B
$2.42M 0.96%
91,500
+6,200
+7% +$176K
2023 Q4
2 quarters
IRWD icon
21
Ironwood Pharmaceuticals
IRWD
$626M
$2.41M 0.96%
370,000
+94,000
+34% +$665K
2024 Q1
1 quarter
CSX icon
22
CSX Corp
CSX
$89.9B
$2.34M 0.93%
70,000
– –
2022 Q4
6 quarters
ESGR icon
23
DELISTED
Enstar Group
ESGR
$2.29M 0.91%
7,500
– –
2024 Q1
1 quarter
TVTX icon
24
Travere Therapeutics
TVTX
$5.17B
$2.19M 0.87%
265,966
+35,000
+15% +$236K
2023 Q3
3 quarters
SNDX icon
25
Syndax Pharmaceuticals
SNDX
$1.24B
$2.13M 0.85%
103,826
+38,351
+59% +$803K
2024 Q1
1 quarter
1
2 3 4 5

Similar funds

SCA
Sander Capital Advisors Seattle, Washington $189M AUM 13.06% 1-Year Est. Return
FI
FWG Investments Lexington, Kentucky $189M AUM 18.47% 1-Year Est. Return
MFS
Madrid Financial Services Manhattan Beach, California $189M AUM 30.12% 1-Year Est. Return
FRA
FFG Retirement Advisors Centennial, Colorado $189M AUM 16.39% 1-Year Est. Return
CAM
Councilmark Asset Management Knoxville, Tennessee $189M AUM 26.93% 1-Year Est. Return
BAG
Bauman Advisory Group Las Vegas, Nevada $189M AUM
SHC
SALT Holding Corp Wilmington, Delaware $189M AUM 34.63% 1-Year Est. Return
HC
Hara Capital Bellevue, Washington $190M AUM 42.56% 1-Year Est. Return

David M. Knott Jr's Q2 2024 Portfolio in Review

As of Q2 2024, David M. Knott Jr held 112 positions worth $251M, down 11% from $283M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

David M. Knott Jr withdrew a net $32.3M in Q2 2024, closing 13 positions and reducing 10 holdings. Its most notable exit was FTAI Aviation, an estimated $16.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 30% a quarter earlier, followed by Materials and Financials.

Against the trend, David M. Knott Jr opened a new position in BioCryst Pharmaceuticals worth $1.94M.

  • David M. Knott Jr's largest Q2 2024 buy was BioCryst Pharmaceuticals: 314,307 shares worth $1.94M.
  • David M. Knott Jr added most to DocGo in Q2 2024, an estimated $3.77M increase.
  • David M. Knott Jr's biggest Q2 2024 reduction was Panagram BBB-B CLO ETF, cutting an estimated $4.73M.
  • David M. Knott Jr fully exited FTAI Aviation in Q2 2024, selling an estimated $16.8M.
  • David M. Knott Jr's ten largest holdings make up 68% of its $251M portfolio in Q2 2024.
  • David M. Knott Jr opened 6 new positions and closed 13 in Q2 2024.
  • David M. Knott Jr's portfolio value fell 11% quarter-over-quarter to $251M.

Based on David M. Knott Jr's 13F filing for Q2 2024, filed 12 Aug 2024.